Geode Capital Management LLC Buys 20,230 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO)

Geode Capital Management LLC grew its holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO) by 6.0% during the 4th quarter, Holdings Channel reports. The firm owned 358,422 shares of the company’s stock after purchasing an additional 20,230 shares during the period. Geode Capital Management LLC’s holdings in Xilio Therapeutics were worth $342,000 at the end of the most recent quarter.

Separately, Takeda Pharmaceutical Co. Ltd. acquired a new position in Xilio Therapeutics during the fourth quarter valued at approximately $1,416,000. 54.29% of the stock is owned by institutional investors and hedge funds.

Xilio Therapeutics Trading Down 0.6 %

Shares of Xilio Therapeutics stock opened at $0.75 on Friday. Xilio Therapeutics, Inc. has a 12 month low of $0.62 and a 12 month high of $1.70. The company has a market capitalization of $38.84 million, a PE ratio of -0.44 and a beta of -0.25. The stock’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $0.92.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The business had revenue of $1.72 million for the quarter, compared to analyst estimates of $2.26 million. Analysts predict that Xilio Therapeutics, Inc. will post -1.14 EPS for the current fiscal year.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.